NEW YORK, Aug. 7 /PRNewswire-FirstCall/ -- Medicsight PLC, a subsidiary of MGT Capital Investments, Inc. (Amex: MGT), and an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software, today announced that it has received approval from the Brazilian regulatory agency, Agencia Nacional de Vigilancia Sanitaria ("ANVISA"), for its ColonCAD(TM) software.
David Sumner, Chief Executive of Medicsight, commented: "This is another important milestone for Medicsight and our partners as we commercialize our technology globally. This regulatory approval in the dynamic Latin American market is another approval in a high growth BRIC market, following on from the Chinese State Food and Drug Administration approval announced in April."
Dr. Stuart Taylor of University College Hospital, London, a principal investigator for Medicsight, commented: "The approval of Medicsight's ColonCAD(TM) software is great news for patients. It will also be a bonus for radiologists, whose workload is growing rapidly, both due to the rising prevalence of colorectal cancer and the advances in imaging technology which have led to a substantial increase in the amount of image data that must be reviewed for each patient scan. Medicsight's technology can help to ease this burden, potentially reducing human error and also providing a valuable tool, especially for less experienced readers, to interpret these complex scans.
"Medicsight's CAD software has been validated against one of the world's largest and most population diverse proprietary databases of verified CT scan data, making the software applicable to patients of many different nationalities," concluded Dr. Taylor.
Medicsight's ColonCAD(TM) computer-aided det
|SOURCE MGT Capital Investments, Inc.|
Copyright©2008 PR Newswire.
All rights reserved